The investigator-initiated VERONICA-Nigeria trial randomised 300 self-identified Black African adults with uncontrolled hypertension from Nigeria 1:1 to a triple pill-based treatment protocol or to the standard-of-care Nigerian hypertension treatment protocol, which starts with 1 agent and may be changed to 2 agents if the result is insufficient. Prof. Dike Ojji (University of Abuja, Nigeria) and colleagues looked at the change in home-measured systolic BP at 6 months.
After 6 months of treatment, participants in the triple pill group had an average 5.8 mmHg lower systolic BP than those in the standard-of-care group. For diastolic BP, the corresponding number was 3.6 mmHg. Furthermore, 62% of the participants in the experimental arm versus 28% of those in the control arm had achieved a BP <130/80 (P<0.001).
“No patients in either study arm had discontinued treatment due to adverse events,” continued Dr Ojji. “The only safety issue we noticed was a slight increase in hypo-potassium (<3.5 mmol/L) in the triple pill arm (34% vs 18%).” When the researchers looked at participants with a potassium level <3.0 mmol/L, they noticed that the proportion had dropped from 34% to 9% in the experimental arm.
In conclusion, the triple pill protocol was more effective than the standard-of-care BP protocol in lowering BP in Black African patients. The BP control rate at 1 month was 80%, which was maintained throughout the study.
- Ojji D, et al. VERONICA-Nigeria - deliVERy of Optimal blood pressure coNtrol in afrICA. HOTLINE 2, ESC Congress 2024, 30 Aug–02 Sept, London, UK.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Does RAS inhibitor discontinuation affect outcomes after non-cardiac surgery? Next Article
HELIOS-B: Vutrisiran candidate for SoC in ATTR cardiomyopathy »
« Does RAS inhibitor discontinuation affect outcomes after non-cardiac surgery? Next Article
HELIOS-B: Vutrisiran candidate for SoC in ATTR cardiomyopathy »
Table of Contents: ESC 2024
Featured articles
STEEER-AF: Shockingly low adherence to ESC atrial fibrillation guidelines
FINEARTS-HF: Finerenone helps across ejection fraction spectrum
Online First
RESHAPE-HF2: Not a “tie-breaker” about TEER in heart failure
MIRACLE-AF: Elegant solution to improve AF care in rural China
MRAs show varied efficacy in heart failure across ejection fractions
SCOFF: To fast or not to fast, that’s the question
SWEDEGRAFT: Can a ‘no-touch’ vein harvesting technique improve outcomes in CABG?
SUPPRESS-AF: What is the value of LVA ablation added to PCI in AF?
STEEER-AF: Shockingly low adherence to ESC atrial fibrillation guidelines
NOTION-3: TAVI plus PCI improves outcomes in CAD plus severe aortic stenosis
RHEIA: TAVI preferred over surgery in women with aortic stenosis
ABYSS: Can beta-blocker safely be interrupted post-MI?
MATTERHORN: Transcatheter repair matches surgery for HF with secondary mitral regurgitation
OCEANIC-AF: Asundexian does not meet expectations for stroke prevention in AF
FINEARTS-HF: Finerenone helps across ejection fraction spectrum
EPIC-CAD: What is the best antithrombotic approach in high-risk AF plus stable CAD?
HELIOS-B: Vutrisiran candidate for SoC in ATTR cardiomyopathy
VERONICA-Nigeria: Improving BP control in Africa with a simple strategy
Does RAS inhibitor discontinuation affect outcomes after non-cardiac surgery?
Novel approach to manage severe tricuspid regurgitation proves its value
Related Articles
September 4, 2024
MRAs show varied efficacy in heart failure across ejection fractions
September 2, 2024
VERONICA-Nigeria: Improving BP control in Africa with a simple strategy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com